These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33913590)

  • 1. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
    Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
    Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
    Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
    Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
    Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
    Rekhi B; Upadhyay P; Ramteke MP; Dutt A
    Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
    Alaggio R; Zhang L; Sung YS; Huang SC; Chen CL; Bisogno G; Zin A; Agaram NP; LaQuaglia MP; Wexler LH; Antonescu CR
    Am J Surg Pathol; 2016 Feb; 40(2):224-35. PubMed ID: 26501226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation profiling reveals novel molecular classes of rhabdomyosarcoma.
    Clay MR; Patel A; Tran Q; Hedges DJ; Chang TC; Stewart E; Charville G; Cline C; Dyer MA; Orr BA
    Sci Rep; 2021 Nov; 11(1):22213. PubMed ID: 34782706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.
    Szuhai K; de Jong D; Leung WY; Fletcher CD; Hogendoorn PC
    J Pathol; 2014 Feb; 232(3):300-7. PubMed ID: 24272621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
    Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
    Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
    Rekhi B; Dodd L; Dharavath B; Dutt A
    Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases].
    Yang L; Zhang HJ; Yang SJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670
    [No Abstract]   [Full Text] [Related]  

  • 12. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
    Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
    J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
    Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
    Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
    Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
    Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Role and Clinical Implications of
    Di Carlo D; Chisholm J; Kelsey A; Alaggio R; Bisogno G; Minard-Colin V; Jenney M; Dávila Fajardo R; Merks JHM; Shipley JM; Selfe JL
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.
    Walther C; Mayrhofer M; Nilsson J; Hofvander J; Jonson T; Mandahl N; Øra I; Gisselsson D; Mertens F
    Genes Chromosomes Cancer; 2016 Jan; 55(1):3-15. PubMed ID: 26482321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.